Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan:161:105857.
doi: 10.1016/j.rmed.2019.105857. Epub 2019 Dec 28.

The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease

Affiliations
Free article
Review

The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease

Donald A Mahler. Respir Med. 2020 Jan.
Free article

Abstract

Inhalation therapy is the mainstay of chronic obstructive pulmonary disease management, and inhaler selection can have a profound impact on drug delivery and medication adherence, as well as on treatment outcomes. Although multiple delivery systems, such as pressurized metered-dose inhalers, dry powder inhalers, slow-mist inhalers, and nebulizers, are available, clinical benefits achieved by patients rely on effective delivery of the inhaled medication to the airways. Among several factors influencing drug deposition, inspiratory flow is one of the most important. Inspiratory flow impacts drug delivery and subsequent clinical efficacy, making it necessary to adequately train patients to ensure correct inhaler use. Peak inspiratory flow is the maximal airflow generated during a forced inspiratory maneuver. Health care professionals need to select the appropriate delivery system after carefully considering patient characteristics, including lung function, optimal inspiratory flow, manual dexterity, and cognitive function. Herein, the role of inspiratory flow in the selection and use of inhaled therapy in patients with COPD is reviewed.

Keywords: Chronic obstructive pulmonary disease; Hand-held inhalers; Inhalation technique; Inspiratory flow; Peak inspiratory flow.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Donald A. Mahler has participated in advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sunovion, and Theravance. He is on the speakers’ bureau for AstraZeneca, Boehringer Ingelheim, and Sunovion. He has received royalties from Hillcrest Media for COPD: Answers to Your Question, 2015; CRC Press for Dyspnea: Mechanisms, Measurement, and Management, 3rd edition, 2014; and pharmaceutical companies for use of the baseline and transition dyspnea indexes.

Publication types

MeSH terms

LinkOut - more resources